lymphocytes

[Century Therapeutics] Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.

[AlloVir, Inc.] AlloVir, Inc. announced that the US FDA has granted its lead multi-virus specific T cell therapy, posoleucel, RMAT designation for the treatment of AdV infection following allogeneic hematopoietic stem cell transplant. The designation is based on positive results from the Phase II CHARMS study.

[Scientific Reports] The impacts of differential r/r B-ALL tumor burdens on the clinical therapeutic efficacy and safety profiles after ssCART-19 cell treatment were analyzed.

[Blood Advances] The authors defined the prevalence and variation of clonal hematopoiesis of indetermined potential (CHIP) over time and assessed the influence on clinical inflammation syndromes, cytopenia and outcome.

[Cancer Gene Therapy] Scientists discuss different generations, challenges, and clinical studies related to chimeric antigen receptor (CAR) T cells for ALL treatment.

[Oncogene] Investigators showed that oral administration of propranolol delayed tumor progression of MCA205 fibrosarcoma model and MC38 colon cancer model and increased the survival rate of tumor bearing mice.